Key result
Protein kinase C isozymes play critical roles in specific aspects of cardiac remodelling and dysfunction in heart failure.
Answers are grounded in this paper and cite their sources.
This review highlights the role of Protein kinase C (PKC) isozymes in cardiac remodeling and their potential as therapeutic targets in heart failure.
Heart failure (HF) afflicts about 5 million people and causes 300,000 deaths a year in the United States alone. An integral part of the pathogenesis of HF is cardiac remodelling, and the signalling events that regulate it are a subject of intense research. Cardiac remodelling is the sum of responses of the heart to causes of HF, such as ischaemia, myocardial infarction, volume and pressure overload, infection, inflammation, and mechanical injury. These responses, including cardiomyocyte hypertrophy, myocardial fibrosis, and inflammation, involve numerous cellular and structural changes and ultimately result in a progressive decline in cardiac performance. Pharmacological and genetic manipulation of cultured heart cells and animal models of HF and the analysis of cardiac samples from patients with HF are all used to identify the molecular and cellular mechanisms leading to the disease. Protein kinase C (PKC) isozymes, a family of serine-threonine protein kinase enzymes, were found to regulate a number of cardiac responses, including those associated with HF. In this review, we describe the PKC isozymes that play critical roles in specific aspects of cardiac remodelling and dysfunction in HF.
No takes yet. Share an insight, caveat, or question.
Palaniyandi et al. (2008) conducted a review in Heart failure. Protein kinase C (PKC) isozymes was evaluated. Protein kinase C isozymes play critical roles in specific aspects of cardiac remodelling and dysfunction in heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: